A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer

NCT06636435 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

66

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors
Hepatocellular Carcinoma (HCC)
Malignant Melanoma
Pediatric Cancer

Interventions

DRUG: CBA-1205 Part 1
DRUG: CBA-1205 Part 2
DRUG: CBA-1205 Part 3
DRUG: CBA-1205 Part 4
DRUG: CBA-1205 Part 5

Sponsor

Chiome Bioscience Inc.